Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIM: Meclizine in Hepatocellular Carcinoma
NCT03253289Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of meclizine in hepatocellular carcinoma (HCC). Primary endpoint: Change in mRNA levels of CAR target genes (CYP2B6, MYC, FOXM1). Started Oct 2017; status: completed.
02
Drugs
meclizine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03253289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253289.